FCF of -$2.1B reflects OCF of -$1.9B plus ~$200M in capex, including the Norwood manufacturing expansion and global facility buildout (Australia, UK, Canada). Management is investing in manufacturing infrastructure during a period of negative cash generation — a bet that future products will need production capacity that cannot be built overnight.

Revenue declined from $6.8B (FY2023) to $3.2B (FY2024) to $1.9B (FY2025) — a 72% collapse in two years. The filing attributes this to declining COVID vaccination rates, competitive pricing pressure, and limited RSV market uptake. Loss per share improved from -$12.33 to -$9.28 to -$7.26, but only because losses are shrinking slower than revenue — cost cuts, not revenue recovery.

The filing warns of 'intensely competitive' vaccine markets and notes Moderna has been 'excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026.' Pfizer is the direct competitor with deeper distribution. Annual COVID boosters are becoming commoditized with declining uptake rates. No durable pricing power exists.

mRESVIA is approved in 40 countries for adults 60+, but the filing acknowledges Moderna 'entered a market already occupied by two larger competitors' (GSK's Arexvy and Pfizer's Abrysvo). Advisory committee recommendations were 'more limited than anticipated,' suggesting the market is smaller and more contested than hoped. Third-mover disadvantage in vaccines is severe — physician habits and formulary positions are already established.

FCF of -$2.1B on $1.9B revenue yields a deeply negative FCF margin. The company is spending $2 for every $1 of revenue. This reflects simultaneous investment in global manufacturing expansion (Norwood, Australia, UK, Canada), a 25-candidate clinical pipeline, and commercial operations for three products. The spending may be rational if pipeline products succeed, but the current economics are unsustainable.

At -$2.1B FCF per year, Moderna is consuming cash reserves at an alarming rate. The $1.5B credit facility provides some buffer, but $500M of it requires regulatory milestones. Management's stated goal of reaching cash breakeven depends on successful product launches — the filing warns 'if we do not successfully implement our cost efficiency and prioritization programs, we may fail to meet our cash breakeven goal.'

Revenue collapsed from $6.8B to $1.9B in two years. The filing warns of 'regulatory uncertainty and evolving regulatory and public health guidance,' changes in 'FDA regulatory policies, post-marketing safety monitoring,' and 'CDC and ACIP recommendations' that 'may have affected and may continue to affect demand.' Vaccination rates may be 'lower than expectations due to viral evolution, medical need and consumer motivation.' This is structural demand destruction.

The filing candidly warns that 'our broad clinical success and post-pandemic commercial challenges have necessitated a more selective and paced approach to our research and development investment' and 'as we pursue development of our prioritized programs, we may forego or delay pursuit of other opportunities that could prove to have greater commercial potential.' The flu vaccine BLA faced an initial refusal-to-file, requiring an amended submission. Pipeline risk is not theoretical — it is actively manifesting.

The filing notes 'changes at U.S. regulatory agencies impacted policies and priorities related to our industry' including 'changes in FDA regulatory policies, post-marketing safety monitoring, and evidentiary expectations.' For a company whose entire future depends on FDA approvals for flu, flu+COVID combo, norovirus, and oncology products, regulatory uncertainty is existential. New post-marketing commitments have also 'impacted costs.'